Brian Piekos Net Worth

Brian Piekos biography

Brian Piekos has been appointed as Chief Financial Officer of the Company effective 8/13/2020. He joined AMAG in 2015 and has held a number of senior management positions with the Company. In his role as Chief Financial Officer, he will act as the Company’s principal financial officer and principal accounting officer and oversee the accounting, corporate finance, and investor relations teams. He has more than 20 years of corporate finance experience including strategic planning, financial reporting and capital market activities. Prior to AMAG, he held positions of increasing responsibility at Cubist Pharmaceuticals. Mr. Piekos began his career in investment banking having served as Vice President at Leerink Partners and as an analyst at Needham & Company.

How old is Brian Piekos?

Brian Piekos is 46, he's been the Chief Financial Officer of AMAG Pharmaceuticals since 2020. There are 9 older and 3 younger executives at AMAG Pharmaceuticals. The oldest executive at AMAG Pharmaceuticals, Inc. is Davey Scoon, 73, who is the Independent Director.

What's Brian Piekos's mailing address?

Brian's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.

Insiders trading at AMAG Pharmaceuticals

Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C.... y Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.

What does AMAG Pharmaceuticals do?

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

AMAG Pharmaceuticals executives and stock owners

AMAG Pharmaceuticals executives and other stock owners filed with the SEC include:

• Joseph Vittiglio,
  Executive Vice President, General Counsel, Corporate Secretary, Chief Business Officer
• Anthony Casciano,
  Chief Operating Officer, Executive Vice President and Chief Commercial Officer
• Gino Santini,
  Independent Chairman of the Board
• Kathrine O'Brien,
  Independent Director
• Anne Phillips,
  Independent Director
• Davey Scoon,
  Independent Director
• John Fallon,
  Independent Director
• James Sulat,
  Independent Director
• David Johnson,
  Independent Director
• Paul Fonteyne,
  Independent Director
• Linda Lennox,
  Vice President - Investor Relations and Corporate Communications
• Nancy Griffith,
  Vice President - Scientific Communications And Medical Operations
• Kelly Schick,
  Chief Human Resource Officer, Senior Vice President
• Brian Piekos,
  Chief Financial Officer
• Scott Myers,
  President, Chief Executive Officer, Director
• Barbara Deptula,
  Director
• Brian P Kelley,
  Director
• Lesley Russell,
  Director
• Robert J Perez,
  Director
• Edward H Myles,
  COO & CFO
• William K Heiden,
  President & CEO
• Nicholas Grund,
  Chief Commercial Officer
• Elizabeth Scott Bolgiano,
  Chief Human Resources Officer
• Partners Lp Caligan,
  10% owner
• Julie Krop,
  Chief Medical Officer
• James Alan Butcher,
  EVP, Chief Business Officer
• Capital Management Lp Camber,
  
• Capital, Llc Armistice Capi...,
  
• Kenneth H Wilson,
  SVP, Sales and Marketing
• Geoffrey Crouse,
  EVP
• Edward P. Jordan,
  SVP, Sales and Marketing
• Scott B Townsend,
  SVP, General Counsel
• Capital Partners Gp, L.L.C....,
  
• Steven Caffe,
  SVP, Ch. Dev. and Reg. Officer
• Ron Zwanziger,
  Director
• Michael Narachi,
  Director
• Sheldon L Bloch,
  Director
• Christopher G White,
  Chief Business Officer and SVP
• Jerome M Lewis,
  VP of Scientific Operations
• David Arkowitz,
  CFO & Chief Business Officer
• Jerome Goldstein,
  CEO and Treasurer
• Ricardo Zayas,
  Sr. Vice President, Operations
• Mark B Skaletsky,
  Director
• Silva Rajiv De,
  Director
• Gary J Zieziula,
  EVP, Chief Commercial Officer
• Michael D Loberg,
  Director
• Frank E Thomas,
  President & COO
• Michael N Avallone,
  VP-Finance and CFO
• Scott A Holmes,
  Chief Accounting Officer
• Joseph Vincent Bonventre,
  Director
• Brian Jg Pereira,
  President and CEO
• Greg Madison,
  EVP, Chief Commercial Officer
• Theodore I Steinman,
  Director
• Edward B Roberts,
  Director
• Timothy G Healey,
  SVP-Commercial Operations
• Lee F Md Ph D Allen,
  CMO & SVP Clinical Dev.
• Joseph L Farmer,
  Gen Counsel & VP Legal Affairs
• Louis Md Brenner,
  Senior Vice President